학술논문
A randomized phase I/II study of neoadjuvant treatment with 177 -Lutetium-PSMA-617 with or without ipilimumab in patients with very high-risk prostate cancer who are candidates for radical prostatectomy (NEPI trial).
Document Type
Article
Author
Source
Journal of Clinical Oncology; 2024 Supplement 4, Vol. 42, pTPS352-TPS352, 97p
Subject
Language
ISSN
0732183X